HDL Metabolism, Cholesterol Efflux and Relationship to Atherosclerosis

1 ACPE 1 ANCC Contract Hours 1 CDR 1 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
Professor of Medicine
Mount Sinai School of Medicine
Cardiometabolic Disorders
Mount Sinai Heart
New York, NY

Robert S. Rosenson, MD, is Professor of Medicine at the Mount Sinai School of Medicine where he serves as Director of Cardiometabolic Disorders.

Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana.  He then served his residency in medicine at Brigham and Women's Hospital in Boston, Massachusetts. He later completed a fellowship in cardiology at the University of Chicago that was followed by an additional year of training as a Research Associate in lipoprotein metabolism

Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy, hypoglycemic therapy, and antihypertensive agents in inflammation, thrombogenesis, and rheology. He has served as Principal Investigator on a number of NIH-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. Recently, he served as Global Principal Investigator of the PLASMA I, PLASMA II and FRANCIS trials.  He has been an invited speaker at more than 200 national and international association meetings, grand rounds, and symposia. He has authored nearly a total of 600 journal articles, book chapters, abstracts, and electronic publications for Up To Date Medicine.

H. Bryan Brewer, Jr., MD, FNLA

H. Bryan Brewer, Jr., MD, FNLA
Director, Washington Cardiovascular Associates
Senior Research Consultant
Lipoprotein and Atherosclerosis Research
MedStar Research Institute
Washington Hospital Center
Washington, DC

H. Bryan Brewer Jr., MD is Director, Washington Cardiovascular Associates, Senior Research Consultant , Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, a division of MedStar Research Institute, in Washington, DC. Prior to joining MedStar, Dr. Brewer was Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, Maryland, a position he held from 1976 to 2005.

Dr. Brewer is a prominent researcher who has published more than 490 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis. He was a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States, and has served on the editorial boards of several prestigious journals. He is currently on the editorial board of Clinical Lipidology. Dr. Brewer's research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. More recently, he has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis.

A recipient of the JD Lane Investigator Award from the US Public Health Service, Dr. Brewer also received the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious & Service, Distinguished Service Medals from the NIH, George Lyman Duff Memorial Award Lecture, and the Robert I. Levy Award.

Dr. Brewer received his medical degree from Stanford University School of Medicine in California. After completing his internship and residency in internal medicine at Massachusetts General Hospital in Boston, Dr. Brewer joined the NHLBI.

Robert A. Hegele, MD

Robert A. Hegele, MD
Jacob J. Wolfe Distinguished Medical Research Chair
Edith Schulich Vinet Caanaga Research Chair (Tier 1) in Human Genetics
Martha Blackburn Chair in Cardiovascular Research
Distinguished University Professor of Medicine and Biochemistry
University of Western Ontario
Ontario, Canada

Rob Hegele is Distinguished University Professor of Medicine and Biochemistry, University of Western Ontario, and director of the Lipid Genetics Clinic and the London Regional Genomics Centre in London, Ontario.  He received his MD degree from the University of Toronto in 1981.  His specialty training in internal medicine and in endocrinology & metabolism was also in Toronto.  His post-doctoral research fellowships were at Rockefeller University and Howard Hughes Medical Institute, University of Utah.  From 1989-1997 he was on the Faculty of Medicine at the University of Toronto.  In 1997 he joined the Schulich School of Medicine and Dentistry and the Robarts Research Institute at the University of Western Ontario, where he holds the Jacob J. Wolfe Distinguished Medical Research Chair and the Martha Blackburn Chair in Cardiovascular Research.  His lab studies the genetics of lipoprotein metabolism, cardio­vascular disease and diabetes mellitus.  Solely or through collaborations, his lab was first to describe the molecular genetic basis of 12 human diseases.  His lab has also defined much of the genetic basis of such complex traits, including hypertriglyceridemia.  He has contributed to national treatment guidelines for dyslipidemia, hypertension and diabetes.  He is a member of the American Society of Clinical Investigation and the Canadian Academy of Health Sciences, among several other professional organizations.  He has (co-)authored over 460 peer-reviewed publications and has presented >120 times at international meetings.  His work has been cited >11,000 times in the biomedical literature and he is listed in the ISI database as being among the top 1% of highly cited scientists in the world.  He has trained numerous physicians and graduate students. 
1. Identify the genetic causes of low and high serum HDL-C as well as the clinical and research implications of these genetic disorders
2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families